Oncology Venture A/S intends to change its company name to Allarity Therapeutics*
Our mission remains to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.
*Subject to approval of shareholders at the upcoming EGM.
Investor Presentation on 23 September
Life Science Investor Conference by Økonomisk Ugebrev
Oncology Venture will be participating and present at Økonomisk Ugebrev’s Life Science Investor Conference on 23 September 1:30 PM – 6:00 PM CEST.
Advancing Stenoparib into human clinical trials as a potential therapy for COVID-19
Oncology Venture’s PARP inhibitor, Stenoparib, has shown in vitro anti-viral activity against Coronavirus in pre-clinical studies conducted at the Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease test center.
Based on these findings, Oncology Venture plans to advance the compound into human clinical trials as a potential therapy for COVID-19.
The series of pre-clinical studies indicated that Stenoparib showed inhibitory activity against Coronavirus in LLC-MK2 cells as a single agent. In addition, Stenoparib in combination with remdesivir was active in inhibiting SARS-Cov-2, the virus that causes COVID-19, in VERO E6 cells. The concentration of Stenoparib required for virus inhibition was lower in the combination study than in the single agent study.
The two drugs target the virus through unique but different mechanisms of action. Remdesivir blocks the RNA replication enzyme, while Stenoparib, as an inhibitor of PARP1/PARP2 (Poly ADP-Ribose Polymerases) and tankyrase 1 and 2 inhibits virus assembly and inhibits the negative effects of virus infection on the human body such as cytokine storm and necrosis.
The background that led Oncology Venture to initiate testing of Oncology Venture’s PARP inhibitor Stenoparib as a possible treatment of COVID-19 was that another PARP inhibitor, Mefuparib (CVL218), in a scientific publication, had been identified as having promising antiviral activity against the virus that causes COVID-19.
The pre-clinical testing has been conducted at the Pathogen and Microbiome Institute at Northern Arizona University (NAU). NAU built the Pathogen and Microbiome Institute labs in 2008 to enable researchers to handle dangerous pathogens, including research on diseases such as West Nile virus and Zika virus. Oncology Venture’s Stenoparib, formerly called 2X-121, was be the first therapeutic agent to be tested against the COVID-19 virus at the newly launched COVID-19 Testing Service Center at the Pathogen and Microbiome Institute.
EVENTS, PRESENTATIONS & INTERVIEWS
Watch presentation by CEO Steve Carchedi
Oncology Venture’s CEO Steve Carchedi participated in the online investor event “Aktiedagen” on 4 May 2020. Watch the presentation and Q&A.
April 3, 2020
Management’s Remarks Regarding Surveillance Listing
- On April 3, 2020, Oncology Venture was placed on the surveillance list by Nasdaq. This is a result of Nasdaq First North’s policy that a company may be placed on the surveillance list if it enters into an agreement regarding financing through convertible notes without a fixed conversion price and/or fixed amounts of shares to be issued and deemed as working capital.
- On March 31, 2020, Oncology Venture had published its annual reports, audited by PwC (formerly PricewaterhouseCoopers), without any concerning remarks regarding the company’s current or future financial situation. The Annual Report 2019 can be found here.
- In the current economic crisis caused by the Corona virus pandemic, the company’s management strongly believes that the agreement with Negma Group and Park Partners is the best current financing option for the company and all of its shareholders. Over the last weeks the company management has explored several potential, alternative financial arrangements with a range of potential investors, and decided that the current agreement is clearly the best and most cost-efficient agreement to ensure that the company has sufficient financing for 2020 and beyond.
- The management is diligently looking into how to get Oncology Venture removed from the surveillance list at the earliest possible time.
- The company is working continuously and diligently on ensuring the progress of our high-priority pipeline projects: Dovitinib, IXEMPRA®, and 2X-121.
Sean Donahue interviews our Principal Infrastructure Engineer
A remote video interview by Sean Donahue focusing on how Oncology Venture’s need of a high degree of performance, security and flexibility led to a partnership with Citrix and Google Cloud in order to ensure the best possible cloud solution for Oncology Venture.
We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class predictive diagnostics platform.
Founded in 2004 in Denmark and publicly traded on NASDAQ First North (Stockholm).
Robust pipeline of several novel anti-cancer drugs
Robust Pipeline of several novel anti-cancer drugs that address significant cancer markets.
3 prioritized clinical programs
- Stenoparib (formerly “2X-121”)
Best-in-class DRP® platform
Best-in-class DRP® platform creates drug-specific, predictive diagnostics to:
- Help select & treat the most likely responder patients for each of our pipeline drugs.
- Accelerate clinical development of each of our programs.
Strong intellectual property position
Strong intellectual property position with over 30 patents/applications in key world markets, covering DRP® diagnostics for more than 75 different cancer drugs.